Invalidity dossier
US 11680274
Method of increasing the function of an AAV vector
Owner recorded by Google Patents: University of PennsylvaniaSource retrieved 11/18/2026. Recorded ownership may lag transfers.
Added 10/9/2026, 4:01:48 AM
Ownership records and AI summaries may refer to different dates or entities. An asserting party is not proof of current ownership. Check the recorded ownership history and source dates before relying on a claim.
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
AI-generated interpretation, not a determination of patent validity. Check the cited records before relying on it.
Patent Overview — US11680274B2
Title: Method of increasing the function of an AAV vector
Patent number: US11680274B2 | Application: US16/368,758 | Publication: US20190218574A1
Assignee: University of Pennsylvania (original and current assignee, per source)
Key dates (as stated in the source): Priority date 2005-04-07; filing date 2019-03-28; granted/publication date 2023-06-20; adjusted expiration 2027-10-04; status Active.
Inventors: Luk Vandenberghe, Guangping Gao, James M. Wilson
Purpose: The invention provides a method of improving AAV (adeno-associated virus)-derived vectors that are non-functional and/or perform weakly. AAV is described as a small, nonenveloped, icosahedral virus of the Parvovirus family with a single-stranded linear DNA genome of 4.7–6 kb, assigned to the genus Dependovirus. Its non-pathogenicity, broad host range (including non-dividing cells), and potential for site-specific chromosomal integration are cited as making it attractive for gene transfer.
Plain-language scope: The method corrects "singletons"—outlier amino acids in a selected (parental) AAV capsid sequence—by altering one or more singletons so they match the amino acid found at the corresponding position(s) in aligned functional AAV capsid sequences. The stated goal is to increase packaging yield, transduction efficiency, and/or gene transfer efficiency of the selected AAV. The invention also provides modified AAV sequences (with one or more singletons eliminated) and AAV vectors bearing the modified capsids. The excerpt references FIG. 1 as a graph of in vitro 293 transduction of singleton-corrected AAV vectors.
Classifications (examples): C12N15/86 (viral vectors); A61K48/00 (gene therapy); C07K14/005 (viral peptides); C12N2750/141 (dependovirus).
What the excerpt does not establish: It does not set out actual claims, the full specification, sequence listings, experimental results, or claim scope; it does not establish validity, enforceability, or inventorship accuracy. The source notes the legal status shown is an assumption, not a legal conclusion, and that listed assignees may be inaccurate.
Source: https://patents.google.com/patent/[US11680274](/patent/US11680274)/en
Generated 10/10/2026, 12:00:50 AM
Cases on file (0)
Specific litigation cases in our database that name US patent 11680274. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.